







Main Text  Large‐conductance  Ca2+‐activated  K+  (BK)  channels  contribute  to  the  repolarisation  or hyperpolarisation  of  a  wide  variety  of  tissues  including  bladder  and  urethral  smooth muscles.[1‐3] In bladder smooth muscle, BK channels are activated by both the influx of Ca2+ across  the membrane and  the release of Ca2+  from  intracellular stores and are responsible for  the rapid repolarisation phase of  the action potential. Thus, BK channels help  limit  the excitability  of  bladder  smooth  muscle  and  consequently  reduce  its  contractile  behaviour. Meredith et al.,[4] elegantly illustrated the importance of BK channels in controlling bladder contractility  by  demonstrating  that  mutant  mice,  which  lack  the  BKα  subunits,  have overactive bladders and are functionally incontinent.  It is clear from the above studies that BK channels offer a promising target for the treatment of  urinary  incontinence  caused  by  overactive  bladder  (OAB).  In  this  study,  we  have synthesised a new family of BK channel openers, termed the GoSlo‐SR family, that may form scaffold molecules for future development in the treatment of this disease. The predominant cause of OAB is  the uncontrolled,  inappropriate contraction of  the bladder smooth muscle, which  increases  intravesicle  pressure  above  urethral  closure  pressure  causing  urine leakage.[5]  The  current  ‘gold  standard’  therapeutic  treatment  (anticholinergics)  for overactive  bladder  has  compliance  rates  of  <30%,  due  to  unwanted  side  effects  including chronic  constipation  and  dry  mouth.[6]  Consequently,  the  pharmaceutical  industry  has invested  significantly  in  trying  to  target  smooth muscle  function  by  developing  novel  BK channel modulators to help treat disorders such as urinary incontinence.[6‐10]   Although  a  large  number  of  chemically  diverse  BK  channel  openers  have  already  been developed,[8,  9]  only  a  few  studies[11‐13]  have  focused  on  examining  the  effects  of  these compounds across a wide voltage range to include physiological potentials (~−100 mV to 0 mV).[10‐12] Instead, the majority of studies have focused on the ability of compounds to open channels  only  at  potentials  some 50  to  100 mV more  positive  than  a  cell  is  ever  likely  to encounter  in  vivo.  It  appears  that  the majority  of  BK  channel  openers  developed  to  date would have little effect at physiological membrane potentials and this may explain their poor efficacy in clinical trials[7] and subsequent failure to progress to market.  
In this study, we have examined the effects of the GoSlo‐SR family of molecules across a wide range of  potentials  (from −100 mV  to +150 mV).  In  addition, we have  chosen  to measure efficacy of these BK channel openers by calculating the shift  in the voltage required to half maximally  activate  the  channels  (ΔV1/2).  We  have  previously  used  this  approach  to demonstrate  that 10 µM Cibacron Blue (Reactive Blue 2, RB2, see Figure 1A) activated BK channels recorded from bladder smooth muscle cells with ΔV1/2 of ~−50 mV.[11]   However, little  is  known  about  the  minimal  structure  necessary  to  retain  biological  activity  on  BK channels. In an attempt to address this, we embarked on a molecular reduction strategy to examine which minimal  components  of  RB2 were  essential  to  retain  BK  channel  opening activity. The aims of the present study were therefore to (i) identify the pharmacophore of RB2  for  BK  channel  activation  and  (ii)  investigate  the  preliminary  structure  activity relationships of truncated RB2 analogues.   
Experimental Section  
Single Channel Recording:  In  this  study,  we  used  the  inside‐out  configuration  of  the  patch  clamp  technique  (see methods in Supporting Information) with symmetrical 140 mM K+ solutions, to evaluate the ability of a series of anthraquinone analogues (5a‐v, 6) to open BK channels when applied to the cytosolic surface of membrane patches. When voltage ramps (from –150 mV to +100 mV, 
−100 mV to +100 mV or −50 mV to +150 mV) were applied to inside‐out patches obtained from freshly dispersed rabbit bladder smooth muscle cells and bathed with 100 nM Ca2+ at the  cytosolic  face,  a  number  of  distinct,  large‐conductance  (335  ±  5  pS,  n=9)  channel openings could be  readily observed at potentials positive  to +50 mV. When currents were recorded  in  the  presence  of  various  Ca2+  concentrations,  the  voltage  dependence  of activation  shifted  negatively  as  the  [Ca2+]  increased.  Figures  2A‐C  show  typical  single channel  currents  recorded  using  the  voltage  ramps  and  holding  potentials  shown  in  the upper panel of each figure. Note that the currents reversed at 0 mV (the reversal potential for  K+ with  our  recording  conditions). When  activation  curves  for  the  above  experiments were constructed and  fitted with a Boltzmann equation,  the voltage at which  the channels were half maximally activated  (V1/2) was 125 ± 4 mV  in 100 nM Ca2+  from 22 patches. As Figure 2D suggests, this was shifted negatively to 13 ± 5 mV when the [Ca2+] at the cytosolic face  of  the  channel was  increased  to  1 µM  (p<0.05, n=22).  Similarly,  increasing  the  [Ca2+] further to 10 µM, shifted the V1/2 to –88 ± 6 mV (n=12). In a separate series of experiments, we examined the effects of the selective BK channel blocker penitrem A (100 nM, n=6)[14] on these large conductance channels. As Figure 2Ei suggests, large conductance channels could be  recorded  in  the  presence  of  1µM  Ca2+  at  the  cytosolic  face  of  the  channel  and  these currents were abolished in the presence of penitrem A (Figure 2Eii) or when iberiotoxin was applied  to  the  extracellular  surface  of  the  patch  (100  nM,  n=3,  data  not  shown).  Taken together, these data suggest that the large conductance channels recorded in these patches are BK channels and little current remains when BK channels were blocked.  Voltage  ramps were  also  employed  in  experiments  to  examine  the  effects  of  the novel BK channel openers on  these channels.  In all of  these experiments,  the  internal  surface of  the patch was  continually  bathed with  100  nM Ca2+  in  the  absence  and  presence  of  each  test 
compound  and  patches  were  held  at  ‐60  mV.  In  our  first  set  of  experiments,  we  were surprised  to  observe  that  the  commercially  available  1‐amino‐4‐phenylamino‐2‐sulfoanthraquinone,  (Acid  Blue  25,  AB25,  10  µM,  see  Figure  1B  for  structure),  was  as effective as RB2 and shifted the activation V1/2 by –51 ± 10 mV (n=4) compared to –49 ± 11 mV (n=8) in the presence of 10 µM RB2. The phenylamino ring was found to be essential for BK  channel  activation  since  10  µM  bromaminic  acid  (3,  Scheme  1)  failed  to  activate  the channels  and  actually  appeared  to  have  a  modest  inhibitory  effect  as  evidenced  by  the positive shift in ΔV1/2 of 14 ± 9 mV (n=5). 
 
Structure Activity Relationship (SAR):  We  next  designed  and  synthesised  a  small  library  of  compounds  following  a microwave‐ assisted Ullmann coupling reaction as reported in the literature.[15] We have called these 23 analogues  of  the  lead  structure  AB25,  the  GoSlo‐SR  family.  The  effect  of  different substituents on the phenyl ring in the N4‐position was investigated (see Table 1). Eight of the analogues  (marked  with  an  asterisk  in  Table  1)  have  been  reported  previously  to  act  as purinoceptor  antagonists,[16‐18]  ecto‐5′‐nucleotidease  (eN)  inhibitors,[19]  or  ectonucleoside triphosphate  diphosphohydrolase  (E‐NTPDase)  inhibitors,[20]  but  the  remainder  of  the analogues were novel. When we examined the effects of these molecules on BK channels, we found  that  a  significant  number  of  the  compounds were  efficacious BK  channel  activators and  shifted  the  activation  V1/2  in  excess  of  –80 mV  (see  Table  1).  The  introduction  of  an electron donating methyl substituent in the meta‐position (5a)[15, 16, 20] or methoxy group in the ortho‐position (5b)[15, 16, 20] of the phenylamino ring failed to significantly enhance their efficacy on BK channels compared to AB25. However when an ethyl group was substituted in the ortho‐,[16] meta‐, or para‐position (5c‐5e) the ability to shift the voltage required for half maximal  activation  of  the  channels  was  increased  approximately  two‐fold  compared  to AB25.   Interestingly, the introduction of a bulky hydrophobic isopropyl group in the ortho‐, meta‐, and  para‐position  (5f‐5h)  also  increased  the  efficacy  substantially  compared  to  AB25 (p<0.05). Among the three regioisomers 5f‐5h of the isopropyl substituent, the ortho and the 
meta‐isomers  were  more  efficacious  than  the  para‐substituted  isomer.  Furthermore,  we observed that introducing a larger non‐polar benzyl substituent in the meta‐position (5i)[18] 
had a strong impact on the activity and shifted the V1/2 by –120 ± 15 mV (n=6) compared to its para‐isomer[17] (5j, ΔV1/2 –79 ± 5 mV, n=6).   Introduction  of  a  lipophilic  substituent  in  the meta‐position  of  the  phenyl  ring,  such  as trifluoromethyl (5k), also increased the activity significantly compared to AB25 and shifted the V1/2 by –107 ± 7 mV (n=12). Figure 3A shows the structure of this compound (which we have called GoSlo‐SR‐5‐6) and Figure 3B shows the  typical effect of  it when applied  to  the cytosolic face of the patch at a concentration of 10 µM (Figure 3B, blue trace) in the presence of  100  nM  Ca2+.  The  black  trace  shows  the  plot  of  n.Po  (number  of  channels  in  patch multiplied by  the open probability) obtained  in  the presence of 1 µM Ca2+  to  illustrate  the maximal  number  of  channel  openings  in  this  patch.  When  these  data  were  fitted  with  a Boltzmann  equation  (solid  lines)  and  the  activation  V1/2  was  summarised  for  12  similar experiments as shown in Figure 3C, 5k shifted the mean activation V1/2 from 122 ± 4 mV  in the absence of the drug (gray bar) to  16 ± 7 mV in its presence (blue bar). A change in [Ca2+] to 1 µM (black bar) shifted the V1/2 to 23 ± 8 mV in the same patches.   In  four  separate  experiments,  we  examined  if  these  effects  were  abolished  when  BK channels  were  blocked  with  penitrem  A  (100  nM).  To  quantify  this,  we  elicited  currents using the same voltage ramps as above and measured the peak current evoked at +100 mV. In the presence of 100 nM Ca2+, the mean peak current at +100 mV was 160 ± 53 pA and this was  significantly  increased  to  515  ±  95  pA  in  the  presence  of 5k. When  penitrem  A was added in the continued presence of 5k, the peak current at +100 mV was reduced to only 12 ±  2  pA  (p<0.05),  consistent  with  the  idea  that  this  molecule  mediated  its  effects  via activation of BK channels.   The trifluoromethoxy substituent (5l) also had similar effects and shifted the ΔV1/2 by –90 ± 8 mV  (n=6).  Interestingly,  substitution  of  the  sulfonate  group  of 5k  in  the  C‐ring with  its isostere carboxyl group (6) did not significantly alter  its ability  to activate  the BK channel activity,  since  this  compound  still  shifted  ΔV1/2 by  –99  ±  11  mV  (n=7).  However,  the commercially available compound, S175099 (Sigma)  in which the sulfonate group of AB25 was replaced by a hydrogen atom, was inactive and thus failed to shift the activation V1/2 of the BK channels significantly.  
The introduction of an electron withdrawing fluorine atom in both the meta‐positions (5n) and the ortho‐positions (5o) of D‐ring reduced the ability of these molecules to activate BK channels.  The  activity  was  not  altered  when  the  D‐ring  was  substituted  with  electron withdrawing fluorine atom in the single meta‐position (5m). Furthermore, the introduction of  a  hydrophilic  substituent  in  the meta‐position  such  as  CO2H  (5t)[15,  19]  decreased  the activity  significantly  compared  to AB25. The  combination of  a ortho‐carboxylic  acid  group with  para‐fluoro  substitution  (5v),[19]  known  as  potent  and  selective  inhibitor  of  eN was found to be  inactive towards BK channel. When a nitro group was  introduced in the meta‐position  (5u),[16,  18]  the BK channels  activated at more positive voltages,  suggesting  that  it had an inhibitory effect on the channels.  The combination of a meta‐trifluoromethyl group with para‐fluoro substitution (5p) slightly reduced  the  efficacy  compared  to 5k.  The  activity  of 5q  increased  significantly when  the chlorine  atom  replaced  the  fluorine  atom  in  5p.  However,  a  combination  of  a  meta‐trifluoromethyl  group  with  para‐methyl  substituent  furnished  the  most  efficacious compound 5r  in this series, which shifted the activation V1/2 by –142 ± 8 mV (n=12) when applied at a concentration of 10 µM. Figure 3E shows a typical example of the effect of this compound  (which we  have  called  GoSlo‐SR‐5‐44)  and  allows  the  direct  comparison  of  its effects  with  the  less  efficacious  GoSlo‐SR‐5‐6  (Figures  3B‐C).  Although  both  patches  of membrane  shown  in  Figures 3B  and 3E  responded  similarly  to  an  increase  in  [Ca2+]  from 100 nM (gray curves)  to 1 µM (black curves), application of 5r  in  the presence of 100 nM Ca2+  (blue  curve,  Figure  3E)  shifted  the  V1/2  from  105 mV  to  –31 mV,  an  effect  that  was greater  than  that  caused by a 10‐fold  increase  in  [Ca2+]. When  the ΔV1/2 data  from  twelve experiments were summarized, 5r shifted the V1/2 (–142 ± 8 mV) significantly more than 5k (–107 ± 7 mV, p<0.05). Compound 5s did not show any improvement in activity (shifted the V1/2 by –137 ± 11 mV) when a methoxy group replaced the methyl group in 5r, suggesting that  the efficacy of  these BK channel openers depends more on  the hydrophobic nature of the substitution at the para‐position, rather than its electron donating ability.  Given  the  difference  in  efficacy  of  5k  and  5r,  we  next  compared  their  potencies  by constructing concentration effect curves in the continued presence of 100 nM Ca2+. Figure 4A shows  a  summary  concentration  effect  curve  in  which  the  mean  V1/2  was  plotted  in  the absence and presence of various concentrations of 5k. The numbers in parentheses refers to 
the  number  of  patches  exposed  to  each  concentration  of 5k. When  these  data were  fitted with  the  Hill‐Langmuir  equation  (solid  line)  a  mean  EC50  of  2.4  µM  (95%  Confidence Intervals 1.1 µM to 5.3 µM) was obtained. Figure 4B shows a similar experiment in which the effect of increasing concentrations of 5r were also examined. Similar to the effects of 5k, 5r shifted  the  activation  curves  in  a  concentration  dependent  manner  and  when  these  data were  fitted with  the Hill‐Langmuir  equation  (solid  line),  it  yielded  a mean EC50  of  2.3 µM (95%  Confidence  Intervals  1.8  µM  to  2.9  µM).  This  was  not  significantly  different  to  the results obtained with 5k and suggests that although 5r was more efficacious than 5k, there was  little difference  in  the potency of  these two compounds on BK channels.  Interestingly, the  slope  of  the  concentration  effect  curve  for  5r  (mean  Hill  slope  1.8;  95%  Confidence Intervals 1.2 to 2.5) was steeper than for 5k (mean Hill slope 0.9; 95% Confidence Intervals 0.4 to 1.3), perhaps suggesting that there was a change in the extent of cooperativity of the binding sites when 5r was applied.  To  illustrate  how  efficacious  the  GoSlo‐SR  family  of  compounds  were,  we  compared  the effects  of  two  well  established  BK  channel  openers,  NS1619[21]  and  NS11021[12]  on  these currents. Figure 5A shows a typical example in which we applied NS1619 (orange line) at a concentration  of  10  µM,  to  a  patch  containing  approximately  23  BK  channels.  In  this example, the activation V1/2 was only shifted by ~−25 mV in the presence of NS1619. In four similar experiments NS1619 shifted  the V1/2  from 141 ± 6 mV to 116 ± 6 mV as shown  in Figure 5B. Application of 10 µM NS1619 shifted the mean V1/2 by −23 ± 3 mV (n=4), whereas the ΔV1/2 with 10 µM NS11021 in the presence of 100 nM Ca2+ was −53 ± 10 mV (n=7). In contrast, the five GoSlo‐SR compounds shown in the blue bars of Figure 5C shifted the ΔV1/2 in excess of −105 mV (n=6‐12 patches  for each compound). All of  these were significantly more effective  than either NS compound when compared using ANOVA (p<0.01, Dunnett’s post‐hoc test).  As  mentioned  previously,  a  number  of  the  compounds  synthesised  here  have  previously been  disclosed  as  antagonists  of  purinoceptors  (5a,  5b,  5c,  5j,  5u),[16‐18]  E‐NTPDase inhibitors (5a, 5b)[20] or eN inhibitors (5a, 5i, 5t, 5v).[16‐20] However we do not believe that the  BK  channel  agonist  activity  demonstrated  here  results  from  an  interaction  with purinoceptors or by inhibition of either eN or E‐NTPDase, for a number of reasons. We have 
previously shown that suramin,[11] a non‐specific purinoceptor antagonist and ecto‐ATPase inhibitor has no effect on BK channels when applied (at concentrations up to 1 mM) to the cytosolic surface of BK channels in bladder smooth muscle. Furthermore, 5v, which has a 2‐carboxy‐4‐fluorophenyl  ring  as  ring  D,  has  previously  been  shown  to  potently  inhibit  eN with  a  Ki  of  260  nM,[19]  yet  failed  to  significantly  alter  BK  channel  activity  even  at  a concentration  of  10  µM.  Similarly,  it  appears  unlikely  that  the  excitatory  effects  on  BK channels  are  due  to  E‐NTPDase  inhibition  since  application  of  an  inhibitor  of  this, ARL67156,[24]  even  at  a  concentration  of  100  µM  (n=5),  failed  to  significantly  shift  the activation  V1/2  (control  164  ±  8 mV  versus  145  ±  6 mV  in  ARL67156, ΔV1/2=−16  ±  7 mV, p=0.054).   It  is equally unlikely  that  the effects are mediated via an effect on purinoceptors since  the SAR of P2Y12 antagonists[17] based on AB25, suggest that an acidic group in ring D is essential for  this activity. We  find  that  the presence of an acidic group (5t)  in  this  ring significantly impaired the ability of the molecules to enhance BK channel opening activity.   Although the binding domain of these compounds on BK channels is not known at present, the above  study allows us  to hypothesize  that  some  favourable  interactions between non‐polar  groups  (isopropyl  or  benzyl)  in  meta‐position  of  the  phenylamino  ring  and  the hydrophobic residues of  the receptor could account  for  the observed activity of 5g and 5i. Consistent with  this,  the  lack  of  efficacy  of 5t  and 5u  could  be  attributed  to  the  reduced lipophilicity in meta‐position of the D‐ring, thus inducing an unfavourable interaction with a specific region of this ion channel. Furthermore, the data from this study also suggest that an acidic group in C‐ring is essential  for the activity since S175099 failed to significantly alter the activation V1/2 of BK channels. 
 In summary, we have synthesised a series of anthraquinone analogues called the GoSlo‐SR family, that act as openers of BK channels and investigated their efficacy in order to obtain initial  information about  their  structure activity  relationships. Our data demonstrates  that the most efficacious members of the GoSlo‐SR family can shift the activation of BK channels in excess of –100 mV, which would activate these channels at physiological potentials, even in the presence of low [Ca2+]i (100 nM). Further studies to evaluate and develop other lead 
structures with the aim of (i) improving the potency in vitro (ii) assessing the efficacy in vivo and (iii) identifying their site of action on BK channels are in progress. 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Scheme  1:  Reagents  and  conditions:  (i)  Ar‐NH2,  Phosphate  buffer,  Copper  powder, microwave, 100‐120°C, 5‐20 min. 
 
Table 1: Structure and effect of GoSlo‐SR compounds on activation ΔV1/2. The substituents at each  position  are  given  in  each  column.  All  compounds  were  applied  at  10  µM  to  the cytosolic surface of the patch in the presence of 100 nM Ca2+. The change in voltage required for half maximal activation of the channels (ΔV1/2) is shown in the right hand column. Data is quoted as the mean ± standard error of the mean (SEM). Numbers in parentheses represent the number of replicates.    
Figure  1.  Structures  of  Reactive  Blue  2  and  Acid  Blue  25.   Panel  A  shows  the  structure  of Reactive Blue 2 and Panel B shows the structure of Acid Blue 25.  
Figure 2. Large conductance Ca2+‐activated K+ channels in rabbit bladder smooth muscle.  Upper  panels  of  A‐C  show  voltage  ramps  from  –100 mV  to  +100 mV were  applied  in  the presence of 100 nM Ca2+ (A) and 1 µM Ca2+ (B) and from –150 mV to +100 mV in 10 µM Ca2+ (C).  Increasing  Ca2+  at  the  cytosolic  surface  of  the  patch  increased  the  number  of  channel openings and shifted the voltage at which they opened to more negative potentials. This  is reflected  in Figure 2D which shows  the mean activation V1/2  in  the presence of  increasing concentrations of Ca2+ at the cytosolic face of the channel. SEM are smaller than the symbol used for means. Figure 2E shows a typical record of the voltage protocol used to evoke BK currents  in  a  patch  bathed  in  1 µM Ca2+  in  the  absence  (Ei)  and  presence  (Eii)  of  the  BK channel blocker penitrem A.  
Figure 3. Comparison of the effects of GoSlo‐SR‐5‐6 and GoSlo‐SR‐5‐44 on the activation of BK 
channels. Panels A and D show the structure of GoSlo‐SR‐5‐6 and GoSlo‐SR‐5‐44 respectively. Panels  B  and  E  show  the  effect  of  100  nM  (grey  traces)  and  1 µM Ca2+  (black  traces)  on patches  before  application  of  10 µM GoSlo‐SR‐5‐6 and GoSlo‐SR‐5‐44  resepectively  in  the presence of 100 nM Ca2+ (blue traces). Solid lines show Boltzmann fits to the data. Panels C and F show summary bar‐charts from 12 separate experiments in which the mean V1/2 in the presence  of  100  nM  Ca2+  (grey  bars)  and  1  µM  Ca2+  (black  bars)  on  patches  before 
application of 10µM GoSlo‐SR‐5‐6 (blue bars, Panel C) or 10 µM GoSlo‐SR‐5‐44 (blue bars, Panel F).   
Figure 4. Concentration effect curves for GoSlo‐SR‐5‐6 and GoSlo‐SR‐5‐44. Panel A shows the mean activation V1/2 (±SEM) obtained from patches bathed in 100 nM Ca2+ (Control) and in the  continued  presence  of  increasing  concentrations  of  GoSlo‐SR‐5‐6.  Panel  B  shows  the mean activation V1/2 (±SEM) obtained from patches bathed in under control conditions (100 nM  Ca2+)  and  in  the  continued  presence  of  increasing  concentrations  of  GoSlo‐SR‐5‐44. Numbers in parentheses show the number of experiments at each concentration. The solid lines show the fit to the data obtained with the Hill‐Langmuir equation.   


















  Compound  E  R1  R2  R3  R4  R5  ΔV1/2(mV) in  100 nM Ca2+ 
AB25*  SO3Na  H  H  H  H  H  –51±10  (n=4) 
5a*  SO3Na  H  CH3  H  H  H  –57±5  (n=6) 
5b*  SO3Na  OCH3  H  H  H  H  –54±15  (n=3) 
5c*  SO3Na  C2H5  H  H  H  H  –85±9  (n=6) 
5d  SO3Na  H  C2H5  H  H  H  –92±11  (n=9) 
5e  SO3Na  H  H  C2H5  H  H  –81±14  (n=4) 
5f  SO3Na  CH(CH3)2  H  H  H  H  –120±8  (n=6) 
5g  SO3Na  H  CH(CH3)2  H  H  H  –113±5  (n=7) 
5h  SO3Na  H  H  CH(CH3)2  H  H  –83±8  (n=6) 
5i*  SO3Na  H  CH2Ph  H  H  H  –120±15  (n=6) 
5j*  SO3Na  H  H  CH2Ph  H  H  –79±5  (n=6) 
5k  SO3Na  H  CF3  H  H  H  –107±7  (n=12) 
5l  SO3Na  H  OCF3  H  H  H  –90±8  (n=6) 
5m  SO3Na  H  F  H  H  H  –28±13  (n=5) 
5n  SO3Na  H  F  H  F  H  –24±9  (n=6) 
5o  SO3Na  F  H  H  H  F  –28±11  (n=6) 
5p  SO3Na  H  CF3  F  H  H  –83±11  (n=6) 
5q  SO3Na  H  CF3  Cl  H  H  –98±12  (n=6) 
5r  SO3Na  H  CF3  CH3  H  H  –142±8 (n=12) 
5s  SO3Na  H  CF3  OCH3  H  H  –137±11  (n=5) 












5u*  SO3Na  H  NO2  H  H  H  1±23  (n=3) 
5v*  SO3Na  CO2H  H  F  H  H  –4±7  (n=5) 
6  CO2H  H  CF3  H  H  H  –99±11  (n=7) 
































































































D. Summary data 











Eii. Penitrem A (100 nM)









Figure 2. Large conductance Ca2+ activated K+ channels in rabbit bladder smooth 
muscle. 
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Figure 4. Concentration effect curves for GoSlo-SR-5-6 and GoSlo-SR-5-44. 
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5d (GoSlo-SR-5-31): Sodium 1-Amino-4-(3-ethylphenylamino)-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 12.07 (s, 1H), 10.13 (brs, 1H), 8.31-8.23 (m, 2H), 8.08 (s, 
1H), 7.87-7.81 (m, 2H), 7.36 (t, J = 7.6 Hz, 1H), 7.14 (s, 1H), 7.08 (dd, J = 8.0, 20.2 Hz, 2H), 
2.64 (ABq, J = 7.6 Hz, 2H), 1.22 (t, J = 7.6 Hz, 3H). 
HRMS (ES): m/z for C22H17N2O5Na2S [M + Na+], calcd. 467.0654, found 467.0666. 
 
5e (GoSlo-SR-5-97): Sodium 1-Amino-4-((4-ethylphenyl)amino)-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 12.09 (s, 1H), 10.17 (brs, 1H), 8.30-8.26 (m, 2H), 8.00 (s, 
1H), 7.88-7.82 (m, 2H), 7.49 (brs, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.8 Hz, 2H), 2.65 
(ABq, J = 8.0 Hz, 2H), 1.23 (t, J = 8.0 Hz, 3H). 
HRMS (ES): m/z for C22H17N2O5Na2S [M + Na+], calcd. 467.0654, found 467.0662. 
 
5f (GoSlo-SR-5-98): Sodium 1-Amino-4((2-isopropylphenyl)amino)-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 



























1H NMR (400 MHz, DMSO-d6): δ 12.16 (s, 1H), 10.13 (brs, 1H), 8.31-8.29 (m, 2H), 7.89-7.83 
(m, 2H), 7.73 (s, 1H), 7.49-7.46 (m, 1H), 7.32-7.24 (m, 3H), 3.23-3.16 (m, 1H), 1.25 (d, J = 
7.2 Hz, 6H). 
HRMS (ES): m/z for C23H19N2O5Na2S [M + Na+], calcd. 481.0810, found 481.0798. 
 
5g (GoSlo-SR-5-63): Sodium 1-Amino-4-((3-isopropylphenyl)amino)-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 12.10 (s, 1H), 10.13 (brs, 1H), 8.31-8.25 (m, 2H), 8.10 (s, 
1H), 7.88-7.82 (m, 2H), 7.54 (brs, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.18 (s, 1H), 7.10 (t, J = 7.6 
Hz, 2H), 2.96-2.89 (m, 1H), 1.25 (d, J = 6.8 Hz, 6H). 
HRMS (ES): m/z for C23H19N2O5Na2S [M + Na+], calcd. 481.0810, found 481.0816. 
 
5h (GoSlo-SR-5-99): Sodium 1-Amino-4-((4-isopropylphenyl)amino)-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
Rf: 0.4 (20% methanol in ethyl acetate). 
1H NMR (400 MHz, DMSO-d6): δ 12.11 (s, 1H), 10.15 (brs, 1H), 8.30-8.27 (m, 2H), 8.02 (s, 
1H), 7.88-7.83 (m, 2H), 7.51 (brs, 1H), 7.34 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.8 Hz, 2H), 2.97-
2.91 (m, 1H), 1.25 (d, J = 6.4 Hz, 6H). 
HRMS (ES): m/z for C23H19N2O5Na2S [M + Na+], calcd. 481.0810, found 481.0827. 
 




















Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 12.05 (s, 1H), 10.12 (brs, 1H), 8.30-8.26 (m, 2H), 8.07 (s, 
1H), 7.87-7.84 (m, 2H), 7.51 (brs, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.32 (s, 2H), 7.31 (s, 2H), 
7.21-7.17 (m, 2H), 7.12 (d, J = 8.0 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 3.98 (s, 2H). 
HRMS (ES): m/z for C27H19N2O5Na2S [M + Na+], calcd. 529.0810, found 529.0834. 
 
5j (GoSlo-SR-5-37): Sodium 1-Amino-4-(4-benzylphenylamino)-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
 
Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 12.07 (s, 1H), 10.11 (brs, 1H), 8.29-8.26 (m, 2H), 8.00 (s, 
1H), 7.88-7.81 (m, 2H), 7.34-7.20 (m, 9H), 3.98 (s, 2H). 
HRMS (ES): m/z for C27H19N2O5Na2S [M + Na+], calcd. 529.0810, found 529.0812. 
 
5k (GoSlo-SR-5-6): Sodium 1-Amino-9,10-dioxo-4-(3-(trifluoromethyl)phenylamino)-9,10-
dihydroanthracene-2-sulfonate 
Rf: 0.4 (20% methanol in ethyl acetate). 
1H NMR (400 MHz, DMSO-d6): δ 11.80 (s, 1H), 10.02 (brs, 1H), 8.24 (dd, J = 7.2, 13.2 Hz, 
2H), 8.04 (s, 1H), 7.85 (m, 2H), 7.65-7.56 (m, 3H), 7.48 (d, J = 7.6 Hz, 1H). 




























5l (GoSlo-SR-5-34): Sodium 1-Amino-9,10-dioxo-4-(3-(trifluoromethoxy)phenylamino)-9,10-
dihydroanthracene-2-sulfonate 
 
Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 11.78 (s, 1H), 10.02 (brs, 1H), 8.27-8.22 (m, 2H), 8.07 (s, 
1H), 7.89-7.82 (m, 2H), 7.54 (t, J = 8.0 Hz, 1H), 7.31-7.28 (m, 2H), 7.12 (d, J = 8.4 Hz, 1H). 
HRMS (ES): m/z for C21H12N2O6F3Na2S [M + Na+], calcd. 523.0164, found 523.0179. 
 
5m (GoSlo-SR-5-15): Sodium 1-Amino-4-(3-fluorophenylamino)-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
Rf: 0.4 (20% methanol in ethyl acetate). 
1H NMR (400 MHz, DMSO-d6): δ 11.83 (s, 1H), 10.05 (brs, 1H), 8.28-8.23 (m, 2H), 8.06 (s, 
1H), 7.89-7.82 (m, 2H), 7.49-7.43 (m, 1H), 7.17-7.11 (m, 2H), 6.99 (dt, J = 2.4, 8.2 Hz, 1H). 
HRMS (ES): m/z for C20H12N2O5FS [M − Na+], calcd. 411.0451, found 411.0464. 
 
5n (GoSlo-SR-5-11): Sodium 1-Amino-4-(2,6-difluorophenylamino)-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
Rf: 0.4 (20% methanol in ethyl acetate). 
1H NMR (400 MHz, DMSO-d6): δ 11.52 (s, 1H), 9.98 (brs, 1H), 8.30-8.27 (m, 2H), 7.89-7.86 
(m, 2H), 7.43-7.30 (m, 4H). 





























5o (GoSlo-SR-5-28): Sodium 1-Amino-4-(4-fluoro-3-(trifluoromethyl)phenylamino)-9,10-
dioxo-9,10-dihydroanthracene-2-sulfonate 
Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 11.73 (s, 1H), 9.99 (brs, 1H), 8.21 (dd, J = 7.2, 15.2 Hz, 2H), 
7.91 (s, 1H), 7.86-7.80 (m, 2H), 7.67-7.63 (m, 2H), 7.57 (t, J = 10.0 Hz, 1H). 
HRMS (ES): m/z for C21H11N2O5F4Na2S [M + Na+], calcd. 525.0120, found 525.0107. 
 
5p (GoSlo-SR-5-40): Sodium 1-Amino-4-(4-chloro-3-(trifluoromethyl)phenylamino)-9,10-
dioxo-9,10-dihydroanthracene-2-sulfonate 
 
Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 11.61 (s, 1H), 9.96 (brs, 1H), 8.24-8.17 (m, 2H), 8.00 (s, 
1H), 7.87-7.80 (m, 2H), 7.72 (s, 1H), 7.71 (d, J = 12.0 Hz, 1H), 7.54 (dd, J = 2.8, 8.8 Hz, 1H). 
HRMS (ES): m/z for C21H11N2O5F3Na2SCl [M + Na+], calcd. 540.9825, found 540.9824. 
 
5q (GoSlo-SR-5-44): Sodium 1-Amino-4-(4-methyl-3-(trifluoromethyl)phenylamino)-9,10-
dioxo-9,10-dihydroanthracene-2-sulfonate 
 
Rf: 0.4 (20% methanol in ethyl acetate).  
1H NMR (400 MHz, DMSO-d6): δ 11.85 (s, 1H), 10.05 (brs, 1H), 8.25-8.20 (m, 2H), 7.97 (s, 
1H), 7.86-7.80 (m, 2H), 7.55 (s, 1H), 7.49-7.44 (m, 2H), 2.45 (s, 3H). 


































Rf: 0.5 (20% methanol in ethyl acetate). 
1H NMR (400 MHz, DMSO-d6): 11.76 (s, 1H), 10.22 (brs, 2H), 8.33 (s, 1H), 8.28-8.22 (m, 2H), 
7.88-7.81 (m, 2H), 7.64-7.59 (m, 3H), 7.44 (d, J = 7.2 Hz, 1H). 


































1H NMR spectra of Newly synthesized anthraquinone analogues: 
 




























































Figure 19: 1H NMR spectrum of 6 (DMSO-d6, 400 MHz) 
 
 
 
 
 
 
 
